Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Research reaches significant milestone in development of F-18 PiB for brain amyloid imaging

AZDEL : 17 January, 2006  (Technical Article)
A key milestone in the imaging of Alzheimer
The imaging of brain amyloid by carbon-11 PiB has been judged by Nature Medicine to be one of the most significant advances in the field of AD in recent years. Multiple sites have now replicated the landmark studies reported by Klunk et al in Annals of Neurology. More recently the U.S.-based Alzheimer’s Association and GEHC have funded a C-11 PIB add-on study to the Alzheimer’s Disease Neuroimaging Initiative, a $60M study to determine the value of brain imaging.

Although C-11 PiB can be used for academic studies, the 20-minute half-life of C-11 and limited manufacturing access means the molecule is not suitable for widespread use as a routine diagnostic agent. F-18, with a half-life of 110 minutes, offers a much better opportunity for manufacturing and distribution.

In 2003, GE Healthcare licensed a number of compounds from the University of Pittsburgh. Proof of concept studies have already been performed in collaboration with GE Healthcare’s IMANET organization, leading to the selection of the lead candidate for further research. Subsequent work has focused on producing the F-18 PiB material to the quality standards necessary for clinical trial use. Don Black, Head of R&D, Medical Diagnostics commented, 'good progress is being made with the set up of the PET centres for the forthcoming trial. Recent news from the University of Pittsburgh about the first subjects injected with F-18 PIB is cause for optimism in the potential use of this agent as a future tool for both diagnosis and therapy monitoring.'

Kim Gallagher, the newly appointed Head of External Affairs, R&D, Medical Diagnostics also remarked, 'these are exciting times in the field of Alzheimer’s Disease. The advent of amyloid imaging agents and the wealth of pharma programs in the area of amyloid targeted therapies, have given real hope that significant progress, in the notoriously slow field of dementia, can be made in the next decade.”
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo